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Rapid and simple enzyme immunoassays (ElAs) were recently developed to measure
2-hydroxyestrone and 16a-hydroxyestrone in unextracted urine. The balance between these
competing estrogen metabolism pathways may serve as a biomarker of breast cancer risk.
Before testing these assays in epidemiologic studies, we evaluated their reproducibility, and
validity relative to gas chromatography-mass spectroscopy (GC-MS). Overnight 12-hr urine
collections from five midfollicular premenopausal women, five midluteal premenopausal
women, and five postmenopausal women were aliquoted and stored at -700C. Two aliquots
from each woman were assayed with the ElAs in a random, blinded order, monthly over
4 months and 1 year later. Reproducibility over 4 months was good for both metabolites in
premenopausal women (coefficient of variation = 8-14%) and satisfactory in postmenopausal
women (-19%). Reproducibility over 12 months remained good in premenopausal women, but
was poor in postmenopausal women, with mean readings increasing 50 to 100%. Wide
variation in estrogen metabolite levels enabled a single EIA measurement to characterize
individual differences among premenopausal women in midfollicular (intraclass correlation
coefficient = 98-99%) and midluteal phase (85-91%). A narrower range in metabolite levels
among postmenopausal women reduced discrimination (78-82%). The correlation between
EIA and GC-MS measurement was excellent for both metabolites (r>0.9), except for
2-hydroxyestrone in postmenopausal women (r=0.6). Analysis of absolute agreement suggested
that both ElAs were less sensitive than GC-MS, and each detected nonspecific background.
The low concentration of estrogen metabolites in urine from postmenopausal women may
explain the problems with reproducibility and validity in this menstrual group. Accordingly, more
sensitive ElAs have been developed and are now being evaluated. Environ Health Perspect
105(Suppl 3):607-614 (1997)
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Introduction
Experimental, epidemiologic, and clinical
evidence strongly suggests that endoge-
nous estrogens influence breast carcino-
genesis although the active form(s) of
estrogen and the specific mechanisms
remain unclear (1). In 1982, the relative
importance of two major, mutually exclu-
sive pathways for estradiol oxidation, 2-
hydroxylation and 16a-hydroxylation, was
postulated to determine a woman's risk of
breast cancer, based on the finding that
estrogen 16a-hydroxylase activity was
increased in women with breast cancer
(2). Over time, the ratio of2-hydroxye-
strone to 16a-hydroxyestrone (the 2/16
ratio) has been emphasized as an indicator
ofthe balance between the two pathways
and ofreduced breast cancer risk. Estradiol
is first reversibly converted to estrone by
17,B oxidation; most ofthe estrone is then
irreversibly oxidized to 2-hydroxyestrone
or 16a-hydroxyestrone, the initial metabo-
lites formed along these two pathways.
Recently, alteration ofthe balance between
these two metabolic pathways has been
proposed as the mechanism by which cer-
tain pesticides, herbicides, plastics, and
other xenoestrogens (foreign estrogens)
may increase the risk ofbreast cancer (3,4)
and by which a low-fat diet (5) or indoles
(6,7) maydecrease the risk.
In vitro studies, using cell cultures and
organ explants, and animal studies indicate
that 16a-hydroxyestrone is a potent estro-
gen, genotoxic, and tumorigenic and that
2-hydroxyestrone is a weak estrogen and
an estrogen antagonist (8,9). Evidence
in humans is more limited. Breast tissue
from breast cancer patients had nearly 5
times more 166a-hydroxylase activity than
comparable tissue from women without
cancer (10). A metabolic study in humans
demonstrated that a decrease in dietary fat
decreased 16a-hydroxylated estrogens in
the urine (5), although studies ofurinary
estrogen profiles in vegetarian and omnivo-
rous women and in women with breast
cancer indicated the relationships are com-
plex (11-13). To our knowledge, the rela-
tionships between breast cancer risk and
2-hydroxyestrone and 16a-hydroxyestrone,
and the two metabolic pathways they rep-
resent, have not yet been examined in a
case-control or cohort study, primarily
because of the difficulty of assessing the
two pathways in humans using radiola-
beled tracer or gas chromatography-mass
spectroscopy (GCMS) methods.
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Recently, rapid and simple enzyme
immunoassays (EIAs) were developed to
evaluate the balance between these two
metabolic pathways, and possibly to serve
as a biomarker ofbreast cancer risk (14).
The EIAs measure 2-hydroxyestrone and
166a-hydroxyestrone in unextracted urine.
The initial studies thatexamined sensitivity,
specificity, coefficients ofvariation, recov-
ery, and validation, relative to a GC-MS
method, have been published (14).
We hope to use these EIAs in a case-
control study of breast cancer in Asian-
American women as one ofmany measures
ofendogenous hormone levels and hor-
mone metabolism that might explain why
breast cancer incidence rates have histori-
cally been 4 to 7 times higher in the
United States than inAsia (15). This large,
population-based case-control study of
breast cancer, conducted among women of
Chinese, Japanese, and Filipino ethnicity
living in San Francisco-Oakland and Los
Angeles, California, and Oahu, Hawaii,
was designed to take advantage of the
diversity in risk and lifestyle in these ethnic
populations and to elucidate the role of
modifiable exposures, related to lifestyle or
environment, in the etiology ofthis disease
(15). In preparation for this effort, we
examined the reproducibility and validity
of a number of hormone assays that we
wish to use with the plasma and urine
samples collected in the study.
Methods
CollectionandDistribution ofSamples
Overnight 12-hr urine samples for the
hormone assays were collected from 15 vol-
unteers working at the National Cancer
Institute, Bethesda, Maryland. Midfollicular
phase urine was obtained 6 to 10 days
after the start of menses from five pre-
menopausal women with regular menstrual
cycles (mean age = 40 years). Midluteal
phase urine was collected 4 to 6 days prior
to the estimated start ofthe next menses
from five premenopausal women with reg-
ular cycles (mean age = 39 years); subse-
quent follow-up confirmed the timing of
the urine collection. Urine was also col-
lected from five postmenopausal women
who had experienced natural menopause
(mean age = 56 years); at least three years
had elapsed since their last menstrual cycle.
None of the 15 women was currently
taking exogenous estrogens.
The 12-hr urines were collected in half-
gallon plasticjugs, containing one teaspoon
of boric acid to acidify the urine and to
prevent bacterial growth. The urine was
kept at-40C with ice packs or refrigeration
until aliquotted the next day. Each urine
sample was decanted from any residue,
carefully mixed, and aliquotted into 10 ml
portions in 15 ml conical tubes for storage
at-70°C.
During March to July 1994, Bradlow's
laboratory received four batches ofurine
aliquots, with one batch to be assayed at
the beginning of each of 4 consecutive
months. Each batch contained two aliquots
from each of the 15 subjects. Within a
batch, the 30 aliquots were randomly
ordered, with a different order for each of
the four batches. A year later, in March
1995, Bradlow's laboratory received a fifth
batch ofrandomly ordered aliquots, this
time with only one aliquot from each of
the 15 subjects. Aliquots were shipped to
the laboratory in identical, sequentially
numbered vials. Laboratory personnel were
told only whether an aliquot was from a
premenopausal or postmenopausal woman.
Also in the springof1995,Adlercreutz's
laboratory received a single batch ofurine
aliquots, containing one aliquot from
each ofthe 15 subjects in a random order.
Laboratory personnel were informed
whether an aliquotwas from a midfollicular
premenopausal, a midluteal premenopausal,
or apostmenopausalwoman.
LaboratoryMethods
In Bradlow's laboratory, 2-hydroxyestrone
and 16a-hydroxyestrone were measured
directly and concurrently in urine with a-
newly developed, commercially available
EIA kit (Estramet 2/16, Immuna Care
Corporation, Bethlehem, PA) (14). High
affinity, specific murine monoclonal anti-
bodies for each metabolite are bound to
microtiter plates, and the enzyme alkaline
phosphatase is linked to each metabolite.
The metabolite in the sample to be assayed
competes with the metabolite:alkaline phos-
phatase to bind to the immobilized anti-
body. The rate ofp-nitrophenol hydrolysis
is inversely related to the concentration of
the metabolite in the sample.
Initially in Bradlow's laboratory, the
urine aliquots were thawed and incubated
with ,B-glucuronidase/sulfatase to hydrolyze
estrogen glucuronides and sulfates. Each
urine aliquot was assayed in triplicate and
the results averaged. Standards of0.625 to
40.0 ng/ml (2.2-140 nmol/liter) were rou-
tinely used (14). For aliquots whose values
fell off the standard curve, either twice
the volume or a dilution ofthe urine was
assayed. The between- and within-assay
coefficients ofvariation for 2-hydroxy-
estrone, 16a-hydroxyestrone, and their
ratio with this EIA kit have been reported
to be consistently less than 9% (14).
In Adlercreutz's laboratory, GC-MS
was used to characterize the estrogen pro-
file in urine after hydrolysis ofconjugates
(16). Fourteen endogenous estrogens-
estrone, estradiol, estriol, 2-hydroxyestrone,
2-hydroxyestradiol, 2-methoxyestrone,
2-methoxyestradiol, 4-hydroxyestrone,
15a-hydroxyestrone, 16a-hydroxyestrone,
16,B-hydroxyestrone, 16-ketoestradiol,
16-epiestriol, and 17-epiestriol-were mea-
sured, along with four lignans and four
isoflavonoids. Each urine aliquotwas assayed
in duplicate andthe results averaged. Briefly,
after protection ofthe carbonyl functions
with O-ethylhydroxylamine, estrogen con-
jugates were extracted on Sep-Pak C18 car-
tridges (Waters Assoc., Milford, MA) and
purified on the acetate form of DEAE-
Sephadex. The aliquots were subsequently
hydrolyzed with Helixpomatia juice and
the hydrolysate purified on the acetate
form of QAE-Sephadex. Recovery after
hydrolysis has been estimated to be 75 to
82%, basedon addition ofdeuterated (d5-)-
ethyloxime derivatives ofall ketonic estro-
gens as internal standards immediately
before this step (17). Estrogens with vici-
nal cis-hydroxyls and diphenolic com-
pounds were fractionated on the borate
and bicarbonate forms ofQAE-Sephadex,
respectively. Neutral steroids were removed
by the free base form ofDEAE-Sephadex,
after which estrogens were separated into
two groups using Lipidex 5000 in a
straight phase system. Following trimethyl-
silyl ether derivatization, estrogens were
analyzed by capillary gas chromatography
with stable isotope dilution mass spectrom-
etry. Deuterated internal standards were
available for all the estrogens except
16a-hydroxyestrone and 17-epiestriol, and
were used to correct for losses after the ini-
tial hydrolysis step. The limit ofdetection
was estimated to be 0.5 to 3 nmol/liter.
The coefficients ofvariation in premeno-
pausal urine samples for the 10 major
estrogens, including 2-hydroxyestrone and
16a-hydroxyestrone, have been reported to
be 4 to 7% (16,17).
SatisticalMethods
The means ofthe triplicate EIA readings
for each aliquot were analyzed on the log
scale (base 10) to reduce the dependence of
the standard deviation ofthe response on
the mean response. The transformation is
also appropriate because-studies ofcancer
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association typically regress log (relative
risk) on the log ofassay results.
For each group ofwomen classified by
menstrual phase, we estimated components
ofvariance among women (GYa2), among
months ofanalysis for a given woman ((Y^),
and among aliquots for a given month ((Y2).
Estimation was based on restricted maxi-
mum likelihood using the SAS procedure
VARCOMP. Withy#kdenotingtheloglo of
the mean assay measurement over triplicates
for woman i=1,2,3,4,5 at monthj(i)=
1,2,3,4 on aliquot k(j) = 1,2, the model is
Results
ReproducibilityofEIAsfor
2- and16a-Hydroxyestrone
The reproducibility ofEIA measurements of
urinary 2-hydroxyestrone and 16ac-hydroxy-
estrone over a 4-month interval is pre-
sented in Figures 1 and 2, respectively.
The estrogen metabolite concentration,
prior to any dilution ofthe urine in prepa-
ration for assay, is plotted on a logarithmic
scale. Each symbol represents the mean of
triplicate measurements; different symbols
distinguish the five women in each men-
strual group. No clear temporal trends
were apparent for either metabolite over
the 4-month interval. Thevariation in mea-
surements taken over several months was
comparable to the variation on a single day
and small compared to the variation in
levels between women. For both metabo-
lites, assay variability was generally compa-
rable in the three groups ofwomen and at
different concentrations ofmetabolite, with
possibly somewhat greater assay variability
in the postmenopausal women. For both
Yijk
" P +a+ b() + F-(ij),
where ai, bj(i), and Ek(ij) are independent
normal variates, each with mean zero and
respective variances Ga2, G2, and a2. The
value of b, the month term, is taken to be
different for each woman and the same for
all assays in that month for that woman.
The term for month is said to be nested
within woman. This nesting is denoted
withj(i). Similarly the effect ofaliquot is
nested within both month and woman,
and this is denoted k(ij). The underlying
mean is p and is regarded as a constant.
Under the model, two assay results
from woman i done in different months
will include the same parameter a.; but the
terms for month and aliquot will be differ-
ent and independent. Thus, the covariance
between measurements arises only from the
term due to the individual. The intraclass
correlation coefficient isGa2/(aG2+Gb2+a2),
i.e., the individual variance component
divided by the sum ofall variance compo-
nents. Coefficients ofvariation measure the
variability associated with a laboratory and
are usually estimated by repeatedly assaying
aliquots from asinglelarge pool anddividing
the standard deviation ofthe measurements
by the mean value. Here the coefficient of
variation was obtained by an application of
the delta method, as in Gail et al. (18). We
approximated the coefficient ofvariation by
100 x 2.303 X(Gsb2 + a2)1/2.
The grand means from the 4-month
reproducibility study were compared with
the corresponding assay results obtained
1 year later using both a paired ttest and a
sign test.
Associations were examined using the
Spearman rank order correlation and, after
log transformation, the Pearson correla-
tion. The Spearman rank order correlation
is the usual correlation coefficient for
ranked outcomes.
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metabolites, between-individual variability
was highest for the midfollicular pre-
menopausal women and lowest for the post-
menopausal women. For women in each
menstrual group, between-individual varia-
tion appeared greater for 2-hydroxyestrone
than 166a-hydroxyestrone.
Apart from the unusually low readings
for both metabolites for one aliquot at month
3 from a midluteal premenopausal woman,
a single EIA measurement, in general, reli-
ably characterized each premenopausal
woman. To see this, note that the lines con-
necting the midpoints ofthe two readings in
each month for each woman are usually
clearlyseparated (Figures 1 and 2). However,
for the postmenopausal women, single EIA
readings were not as reliable for character-
izing an individual woman; in particular,
the midpoint lines cross one another.
Among the postmenopausal women, a
narrower range in metabolite values and,
to a lesser extent, the increased assay vari-
ability contributed to the overlapping lines
and the less definitive discrimination
between women.
For both 2-hydroxyestrone and
16a-hydroxyestrone, the mean ofthe eight
EIA measurements performed on urine
from each woman in the spring of 1994 was
compared with the single repeat measure-
ment made a year later (Figure 3). Readings
for both estrogen metabolites increased,
with the most striking effect seen in the
postmenopausal women. Mean 2-hydroxy-
estrone readings rose in two ofthe midfol-
licular premenopausal women, in five of
the midluteal premenopausal women, and
in five of the postmenopausal women,
while 16o-hydroxyestrone readings rose in
two of the midfollicular premenopausal
women, in four ofthe midluteal premeno-
pausal women, and in all five ofthe post-
menopausal women. With few exceptions,
rankings among women were maintained.
The mean relative increase for each estrogen
metabolite was moderate but not statistically
significant for the midfollicular premeno-
pausal women, modest for the midluteal
premenopausal women, and substantial and
statistically significant for the postmeno-
pausal women (Table 1).
The reproducibility ofEIA measurement
of 2-hydroxyestrone and 16a-hydroxy-
estrone is summarized and quantified in
Table 1. The coefficient ofvariation over a
4-month interval, a measure oflaboratory
variability, was comparable for the two
estrogen metabolites and highest in the post-
menopausal women (19%), the menstrual
group with the lowest concentration of
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Figure 3. Reproducibility over 1 year of EIA measurement of urinary 2-hydroxyestrone and 16ax-hydroxyestrone.
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the 4-month reproducibility study. The 1995 values are for a single aliquot from each woman measured in March
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Table 1. Reproducibility of EIA measurement of urinary 2-hydroxyestrone and 16a-hydroxyestrone.
Coefficient of Intraclass correlation Relative
Mean offivewomena variation coefficient increase
Estrogen metabolite (ng/ml) over4 months, % over4 months over 1 year, %
Midfollicular premenopausal women
2-Hydroxyestrone 44.2(10.6-116.0) 7.8 0.99 20
16a-Hydroxyestrone 13.6(3.2-28.7) 11.1 0.98 25
Midluteal premenopausal women
2-Hydroxyestrone 19.4(7.5-35.8) 13.7b 0.91 6
16a-Hydroxyestrone 10.3(6.0-16.9) 8.9b 0.85 5
Postmenopausal women
2-Hydroxyestrone 5.6(3.3-9.1) 18.7 0.82 57*
16a-Hydroxyestrone 2.4(1.8-4.1) 18.5 0.78 105*
*p < 0.01. "Numbers in parentheses are ranges of individual means. bExcludes the unusually low reading at
month 3 for one aliquot from a midluteal premenopausal woman. Including these low values, the coefficients of
variation for2-hydroxyestrone and 16ax-hydroxyestrone would be 19.2 and 17.3%, respectively.
both metabolites. Laboratory variation
from month to month during the 4-month
interval was no greater than expected,
based on laboratory variation in a single
day (results not shown). The intraclass cor-
relation coefficient, the proportion ofthe
variation in assay results attributable to dif-
ferences between women, was lower in
midluteal premenopausal women than in
midfollicular premenopausal women, and
was lowest in postmenopausal women
(Table 1). In addition, itwas slightly greater
for 2-hydroxyestrone than 166a-hydroxy-
estrone. The intraclass correlation coeffi-
cient approached 99% for each metabolite
in midfollicular premenopausal women
(approximately 10-fold range in metabolite
concentrations among the women) and
dropped to approximately 80% in post-
menopausal women (approximately 3-fold
range in metabolite concentrations).
BiochemicalValidityofEIAs for
2-and16a-Hydroxyestrone
An assay may be highly reproducible but
not valid. For example, the assay may
detect compounds structurally similar to
the analyte ofinterest (lack ofspecificity).
Because of its ability to separate and iden-
tify very similar compounds (excellent
specificity), GC-MS iswidelyaccepted as a
gold standard for measurement ofsteroid
hormones. The correlations between EIA
and GC-MS measurement of2-hydroxy-
estrone, 16a-hydroxyestrone, and the ratio
of2-hydroxyestrone to 160x-hydroxyestrone
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are given in Table 2. The mean ofthe tri-
plicate EIA readings obtained in the spring
of 1995 from one aliquot was compared
with the mean of the duplicate GC-MS
readings conducted at approximately the
same time on a single aliquot. Since the
EIA for 2-hydroxyestrone is known to mea-
sure other C-2 hydroxylated estrogens (14),
GC-MS estimates for 2-hydroxyestrone
and 2-hydroxyestradiol were combined and
compared with the EIA estimate for
2-hydroxyestrone. The Spearman rank
order correlations for the estrogen metabo-
lites were generally high (r . 0.9) except for
2-hydroxyestrone in postmenopausal
women (r = 0.60). Pearson correlations
were similar, with the lowest correlation
(r=0.60) again noted for 2-hydroxyestrone
in postmenopausal women. Correlations
for the 2/16 ratio were no better than those
for the absolute levels ofthe two metabo-
lites, and were lower for postmenopausal
women than premenopausal women.
Because of the limited reproducibility
of the EIAs for both estrogen metabolites
in postmenopausal women and the lower
correlation with GC-MS estimates, regres-
sion analysis of the validity of the EIAs
using GC-MS estimates as the true values
was restricted to the 10 premenopausal
women (Figure 4). The logarithm (base
10) ofthe EIA value was regressed against
the logarithm ofthe GC-MS value to sta-
bilize the variance. Ifthe two measurement
techniques agree perfectly, the slope ofthe
regression line would be 1 and the inter-
cept would be at the origin, as indicated by
the dashed line in each plot. The slopes of
the regressions for both metabolites were
less than 1.0, indicating that both EIAs are
less sensitive than GC-MS. The y-inter-
cepts for both regressions were clearly
above the origin, suggesting that both EIAs
measure compounds other than the ana-
lytes ofinterest or detect nonspecific back-
ground. Nonetheless, despite the imperfect
agreement between the absolute values
generated by the two measurement tech-
niques, the correlations between the two
techniques were high (Table 2). Thus,
among premenopausal women, 87 to 92%
ofthe variance in the EIA estimates ofthe
two metabolites and of the ratio was
explained by the GC-MS measurements.
BiologicSignificance
ofthe2/16 Ratio
Bradlow and colleagues have suggested that
the 2/16 ratio, the ratio of 2-hydroxy-
estrone to 166a-hydroxyestrone, reliably
characterizes the relative importance ofthe
Table 2. Correlation of EIA and GC-MS measurement
of 2-hydroxyestrone, 16a-hydroxyestrone, and the ratio
of 2-hydroxyestrone to 16a-hydroxyestronea.
Spearman
rank order Pearson
Estrogen metabolite correlation correlation
Premenopausal womenb
2-Hydroxyestrone 0.952** 0.943**
16a-Hydroxyestrone 0.952** 0.961**
2/16 Ratio 0.842** 0.932**
Postmenopausal women
2-Hydroxyestrone 0.600 0.601*
16at-Hydroxyestrone 0.900** 0.914**
2/16 Ratio 0.600 0.849**
*p<0.05, **p<0.01. 'The EIA measurement of a sin-
gle aliquot from each woman in the spring of 1995 was
compared with the GC-MS measurement of a single
aliquot also obtained in the spring of 1995. Since the
EIA for 2-hydroxyestrone measures other C-2 hydroxy-
lated estrogens (13), GC-MS estimates for 2-hydroxy-
estrone and 2-hydroxyestradiol were combined.
blncludes the midfollicular and midluteal pre-
menopausal women.
two dominant pathways for estrogen metab-
olism-2-hydroxylation and 16-hydroxyla-
tion (Figure 5). To evaluate this hypothesis,
we assumed that 2-hydroxyestrone and
2-methoxyestrone are the major metabolites
on the 2-hydroxylation pathway and that
16a-hydroxyestrone, 17-epiestriol, and
estriol are the major metabolites on the
16a-hydroxylation pathway (PK Siiteri,
personal communication.) There are differ-
ences ofopinion among endocrinologists
about which estrogen metabolites are the
dominant ones, and whether the same
pattern is seen in all women. Using the
GC-MS results for all 15 women, the ratio
of2-hydroxyestrone to 16a-hydroxyestrone
(the 2/16 ratio) was then compared with the
ratio of (2-hydroxyestrone + 2-methoxy-
estrone) to (16a-hydroxyestrone + 17-
epiestriol + estriol). The correlation was
excellent (Spearman correlation coefficient =
0.90; Pearson correlation coefficient = 0.96)
and is shown in the scatter plot in Figure
6A. In addition, the 2/16 ratio seemed con-
sistently predictive; it reflected the relative
importance ofthe competing pathways for
thewomen in each menstrual group.
In the late 1970s, Lemon and col-
leagues (19,20) hypothesized, on the basis
of mammary carcinogenesis studies in
rodents, that women with a low ratio of
estriol to estrone and estradiol combined
would have a high risk ofbreast cancer.
The hypothesis was thought to explain the
protective effect offull-term pregnancies
(estriol is extremely high relative to the
other two estrogens in the second halfof
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Figure 4. Validation with GC-MS of EIA measurement
of urinary 2-hydroxyestrone, 16a-hydroxyestrone, and
the 2/16 ratio in 10 premenopausal women. The log-
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bined. The dashed line represents the expected regres-
sion ifthe two measurementtechniques agree perfectly.
For 2-hydroxyestrone, the actual regression equation is
log10o (2-hydroxyestrone by EIA) = 0.705 log10 (2-hydrox-
yestrone + 2-hydroxyestradiol by GC-MS) + 0.632; r2 -
0.89. For 16a-hydroxyestrone, the actual regression
equation is log10o (16a-hydroxyestrone by EIA) = 0.597
1og10(16a-hydroxyestrone byGC-MS)+0.811; r2 =0.92.
Forthe2/16 ratio,theactual regressionequation islog10o
(2-hydroxyestrone/16a-hydroxyestrone by EIA) = 0.742
log10 [(2-hydroxyestrone + 2-hydroxyestradiol)/
16a-hydroxyestrone byGC-MS]-0.0869; r2 =0.87.
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Figure 5. Estrogen metabolism in women.
pregnancy) and the higher incidence of
breast cancer in Western than in Asian
countries (21). However, in several case-
control studies, urinary levels of these
estrogens were determined and the calcu-
lated ratio was not convincingly related to
breast cancer risk (21,22). Pike has sug-
gested that the 2/16 ratio should be
inversely related to the ratio estriol/(estrone
+ estradiol) and, therefore, the early epi-
demiologic studies refuting the estriol/
(estrone + estradiol) hypothesis from the
1970s would also tend to refute the more
recent 2/16 hypothesis (MC Pike, personal
communication). In Figure 6B, these two
ratios are compared. The correlation was
only moderate (Spearman correlation
coefficient = -0.65; Pearson correlation
coefficient = -0.64) and was not clearly
seen in all three menstrual groups.
Recently, Adlercreutz et al. (23)
emphasized the evidence, derived from in
vitro studies and possible mechanisms, that
estrogens hydroxylated at the 2 and 4
positions may be carcinogenic. When they
compared the urinary excretion of estrogen
metabolites in 12 premenopausal Finnish
women and 13 premenopausal recent
Asian migrants to Hawaii (who would be
expected to have a substantially lower risk
ofbreast cancer than the Finnish women),
excretion of 166a-hydroxylated estrogens
was similar in both groups. Moreover, the
significantly greater urinary excretion of
total estrogens in the Finnish women was
reflected in substantially elevated urinary
levels of 2- and 4-hydroxylated estrogens.
Total estrogen exposure has long been
postulated as an underlying hormonal
cause ofbreast cancer (1). Thus, we exam-
ined the relationship between the 2/16
ratio and total urinary estrogens (Figure
6C). The correlation among the 15 women
in our study was poor (Spearman correla-
tion coefficient = 0.48; Pearson correlation
coefficient = 0.56).
Discussion
To summarize, laboratory reproducibility
of the EIAs for 2-hydroxyestrone and
16a-hydroxyestrone was good for both
metabolites in premenopausal women
(coefficient ofvariation = 8-14%) and sat-
isfactory in postmenopausal women (coeffi-
cient ofvariation approximately 19%) over
a 4-month interval. Laboratory repro-
ducibility over a 12-month interval contin-
ued to be good for both metabolites in
premenopausal women, but was noticeably
poor in postmenopausal women, with the
mean readings increasing 50 to 100%.
Laboratory reproducibility was similar for
the two metabolites. The sudden develop-
ment of a problem at 12 months, which
was not apparent during monitoring over
4 months, suggests that assay calibration,
rather than analyte stability, was involved.
Wide variation in estrogen metabolite
levels among the women enabled a single
EIA measurement to characterize individual
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Figure 6. Possible biologic significance of the ratio of
2-hydroxyestrone to 16a-hydroxyestrone. To evaluate
different hypotheses, various combinations of urinary
estrogen metabolites are plotted versus the urinary
2/16 ratio for 15 women. All estrogen metabolite esti-
mates, including the 2/16 ratio, are based on the
GC-MS measurements.
differences in the midfollicular phase
premenopausal women (intraclass cor-
relation coefficient = 98-99%) and
in the midluteal phase premenopausal
women (intraclass correlation coefficient =
85-91%). A narrower range in metabolite
levels among the postmenopausal women
reduced discrimination (intraclass correla-
tion coefficient = 78-82%). For women in
each menstrual group, between-individual
variation, relative to laboratory variation,
was greater for 2-hydroxyestrone than
for 16a-hydroxyestrone.
The correlation of EIA measurement
with determination by GC-MS-the gold
standard-was excellent (r > 0.9) for
both estrogen metabolites, except for
2-hydroxyestrone in postmenopausal
women. Correlations for the 2/16 ratio
were no better than those for the individ-
ual metabolites, and thus also lowest for
the postmenopausal women. Absolute
agreement between the two measurement
techniques was evaluated only in the pre-
menopausal women. The EIAs for both
metabolites were less sensitive than GC-MS,
and detected nonspecific background. The
nonspecific background noise tended to
cancel out for the 2/16 ratio.
Thus, this EIA kit seemed to be the
least useful for postmenopausal women.
First, assay reproducibility, particularly
long-term reproducibility, was poor in
postmenopausal women, possibly due to
the low concentration ofboth metabolites.
A moderate change over time in the non-
specific background picked up by the EIAs
would be the most problematic at low con-
centrations ofmetabolite. In addition, lim-
ited between-individual variation in
absolute levels ofboth estrogen metabolites,
compounded by poor reproducibility,
caused the EIAs to be least able to discrimi-
nate between individuals among the post-
menopausal women. Finally, the correlation
between EIA and GC-MS measurements
diverged the most in postmenopausal
women, possibly due to the low levels
of metabolite relative to background
noise. In response to these concerns, new,
more sensitive EIAs have been developed
by TL Klug of Immunacare Corporation
(Bethlehem, PA), and described by
Bradlow (24). We are now evaluating
the reproducibility and validity, relative to
GC-MS, ofthese EIAs.
Certain of our conclusions were based
on small numbers; in particular, our assess-
ment ofvalidity was based on a total of 15
women, with 5 in each menstrual group. A
larger sample ofwomen would also have
strengthened our estimate ofbetween-indi-
vidual variation in levels ofthese two estro-
gen metabolites and its magnitude relative
to laboratory variation.
In addition, we had no information on
within-individual variation in levels ofthese
metabolites-the degree to which different
days of the menstrual cycle, menopausal
status, and age may affect estrogen metabo-
lite levels. Within-individual variability,
as well as laboratory variability, must be
small relative to between-individual varia-
bility for an assay to reliably characterize
an individual.
Our evaluation of the EIAs for
2-hydroxyestrone and 16a-hydroxyestrone
was unusually demanding. Most of the
recent published articles on hormone
measurement techniques have evaluated
only reproducibility, not validity (25-28).
In addition, measurement by GC-MS
may not be absolutely correct. We did not
test the reproducibility of the GC-MS
technique. Adlercreutz et al. (11) esti-
mated that probably 5%, and possibly as
much as 10%, ofthe hormone metabolites
might have been lost in the GC-MS
analysis because of incomplete hydrolysis
prior to the introduction of deuterated
internal standards.
In evaluating the validity ofthese EIAs,
our focus was on biochemical validity,
based on the published specificities ofthe
two monoclonal antibodies. However, our
ultimate interest is in biologic validity-
the ability ofthis EIA kit, and any subse-
quent modifications ofthis kit, to predict
risk ofbreast cancer in individual women.
Even ifthe two antibodies are not totally
specific for 2-hydroxyestrone and 16ax-
hydroxyestrone and cross-react with other
2-substituted and 16a-substituted estrogen
metabolites, respectively, the EIAs may still
provide meaningful measures ofthe com-
petition between these two metabolic path-
ways. Thus, we plan to evaluate these ELAs
in a case-control study ofbreast cancer. By
focusing attention on patterns ofhormone
metabolism, not just absolute hormone
levels, this kit suggests new approaches for
studies of endogenous hormones and
breast cancer.
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